[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Lee KH, Yu CS, Namgung H, Kim HC, Kim JC: Isolated diaphragmatic metastasis originated from adenocarcinoma of the colon. Cancer Res Treat; 2004 Apr;36(2):157-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated diaphragmatic metastasis originated from adenocarcinoma of the colon.
  • Isolated diaphragmatic metastasis arising from colorectal cancer has been reported only one case in the literature presently.
  • Here, we presented a new case and discussed the possible pathogenesis and the treatment options.
  • During a second-look operation, we found a solitary metastasis on the diaphragm and removed it along with the 1 cm tumor-free resection margin.
  • Although the prognosis associated with skeletal metastasis is poor, the complete resection of isolated diaphragmatic metastasis and subsequent appropriate adjuvant chemotherapy may achieve a cure the disease provided that other metastatic lesions are absent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1988 Aug;31(8):636-52 [3042304.001]
  • [Cites] Cancer. 1985 Mar 15;55(6):1284-90 [3971297.001]
  • [Cites] Cancer. 1973 Jan;31(1):226-36 [4683038.001]
  • [Cites] Radiat Med. 1998 Sep-Oct;16(5):363-5 [9862159.001]
  • [Cites] Hepatogastroenterology. 1994 Oct;41(5):405-8 [7851845.001]
  • [Cites] Dis Colon Rectum. 1996 Jan;39(1):74-9 [8601361.001]
  • [Cites] Br J Surg. 1971 Jun;58(6):458-60 [4932851.001]
  • (PMID = 20396557.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2855092
  • [Keywords] NOTNLM ; Carcinoembryonic antigen / Colorectal neoplasm / Diaphragm / Metastasis
  •  go-up   go-down


2. Batirel HF, Metintas M, Caglar HB, Yildizeli B, Lacin T, Bostanci K, Akgul AG, Evman S, Yuksel M: Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol; 2008 May;3(5):499-504
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trimodality treatment of malignant pleural mesothelioma.
  • INTRODUCTION: Multimodality treatment has achieved significant success in local control and treatment of early-stage malignant pleural mesothelioma patients.
  • METHODS: We have instituted a trimodality treatment protocol consisting of extrapleural pneumonectomy, adjuvant high-dose (54 Gy) hemithoracic irradiation, and platin-based chemotherapy in a multi-institutional setting.
  • Preoperative pulmonary function tests, echocardiogram, chest computed tomography, and magnetic resonance imaging scans were performed in all patients.
  • Twelve patients completed all three treatments.
  • Eight patients had extrapleural lymph node involvement (internal mammary [n = 3], subcarinal [n = 2], pulmonary ligament [n = 1], diaphragmatic [n = 1], subaortic [n = 1]).
  • CONCLUSIONS: Trimodality treatment in malignant pleural mesothelioma seems to prolong survival in patients without lymph node metastasis.
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Feasibility Studies. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18449002.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB: Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res; 2005 Oct 1;11(19 Pt 1):6966-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No measurable ascites developed in the treated group.
  • Diaphragmatic and hepatic tumors were not found in the VEGF Trap plus paclitaxel group in contrast to controls, indicating lack of metastasis.
  • In the VEGF Trap plus paclitaxel group, mice were ambulating and eating normally with no signs of disease for at least 81 days after tumor cell inoculation, and survival occurred for 129.9 +/- 38.88 days with no further treatment.
  • We conclude that combination therapy with VEGF Trap plus paclitaxel may provide a novel, long-lasting therapeutic strategy for treatment of patients with ovarian cancer associated with ascites.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Paclitaxel / therapeutic use. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Analysis of Variance. Animals. Apoptosis. Ascites / metabolism. Cell Line, Tumor. Disease Models, Animal. Female. Humans. Mice. Mice, Nude. Necrosis. Neoplasm Metastasis. Neoplasm Transplantation. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203789.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50-CA 83609
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Vascular Endothelial Growth Factor A; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


Advertisement
4. Tamesue K, Hara K, Hara F, Nakajima T: Pericardial reconstruction using a pedicle flap of the diaphragmatic central tendon. Jpn J Thorac Cardiovasc Surg; 2005 Sep;53(9):494-7
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pericardial reconstruction using a pedicle flap of the diaphragmatic central tendon.
  • Chest computed tomography and magnetic resonance imaging revealed a lobulated tumor arising from the left lower lobe.
  • At operation, the tumor tissue was found to have invaded the lingula and pericardium, involving the left phrenic nerve.
  • A pedicle flap of the diaphragmatic central tendon was used as a pericardial patch for pericardial reconstruction with satisfactory results.
  • The postoperative histological diagnosis was pulmonary adenocarcinoma with sarcomatous elements [pT3N2M0].
  • At present, 43 months after the operation, the patient is receiving chemotherapy after having undergone cyberknife radiotherapy for brain metastasis of the tumor.
  • The use of a pedicle diaphragmatic flap was effective in repairing a pericardial defect after extensive resection of pulmonary malignancy.
  • [MeSH-major] Diaphragm. Heart Neoplasms / surgery. Pericardium / surgery. Reconstructive Surgical Procedures / methods. Surgical Flaps
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Female. Humans. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Middle Aged. Neoplasm Invasiveness. Pneumonectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 1993 Mar;55(3):756-7 [8452443.001]
  • [Cites] J Biomed Mater Res. 1991 Oct;25(10):1201-9 [1812116.001]
  • [Cites] J Thorac Cardiovasc Surg. 1961 Mar;41:348-55 [13735019.001]
  • [Cites] J Thorac Cardiovasc Surg. 1983 Jan;85(1):54-8 [6848887.001]
  • [Cites] Ann Plast Surg. 1984 Sep;13(3):234-8 [6497271.001]
  • [Cites] Ann Thorac Surg. 1996 Apr;61(4):1112-4 [8607666.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Dec;118(6):1084-9 [10595982.001]
  • [Cites] Chest. 1997 Nov 5;112(5):1304-9 [9367473.001]
  • [Cites] Ann Thorac Surg. 1975 Aug;20(2):215-36 [1099996.001]
  • (PMID = 16200891.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Harris MA, Radford JA, Deakin DP, James RD, Swindell R, Cowan RA: Limited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma. Clin Oncol (R Coll Radiol); 2004 Feb;16(1):53-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited field radiotherapy for early stage, infra-diaphragmatic Hodgkin's lymphoma.
  • AIMS: To analyse the treatment outcome for patients with stage I and II infra-diaphragmatic Hodgkin's lymphoma.
  • Twenty-five out of 33 patients received radiotherapy alone, three out of 33 patients received minimal initial chemotherapy (MIT) (4 weeks VAPEC B) and five patients received six cycles of ChlVPP EVA hybrid chemotherapy before radiotherapy.
  • The median time to relapse was 37 months (range 7-65 months).
  • All five relapses had received radiotherapy alone and four were salvaged with chemotherapy.
  • CONCLUSIONS: In our cohort of patients with infra-diaphragmatic stage I and II Hodgkin's lymphoma treated with limited-field radiotherapy, no patients died from uncontrolled disease.
  • The use of MIT may reduce the risk of relapse and obviate the need for conventional salvage chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / radiotherapy. Neoplasm Staging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Chlorambucil / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Procarbazine / administration & dosage. Retrospective Studies. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14768756.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 18D0SL7309 / Chlorambucil; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; ChlVPP-EVA regimen; VAPEC-B protocol
  •  go-up   go-down


6. Braune C, Fangmann J, Scheumann GF, Klempnauer J: [Multiorgan resection in combination with intraoperative, hyperthermic chemotherapy in recurrent fibrolamellar hepatocellular carcinoma. An individual therapeutic concept for a 21-year-old patient]. Zentralbl Chir; 2001 Apr;126(4):318-21; discussion 322
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiorgan resection in combination with intraoperative, hyperthermic chemotherapy in recurrent fibrolamellar hepatocellular carcinoma. An individual therapeutic concept for a 21-year-old patient].
  • [Transliterated title] Multiviszerale Resektion in Kombination mit intraoperativer, hyperthermer Chemotherapie beim Rezidiv des fibrolamellären, hepatozellulären Karzinoms. Ein individuelles, therapeutisches Konzept bei einem 21jährigen Patienten.
  • Early stage diagnosis and aggressive surgical treatment achieve better long-term results than usual resection of the HCC.
  • Usually the FLC is, caused by its inconspicuous clinical appearance, diagnosed at a stage too advanced for effective surgical treatment.
  • Especially the young patient's age and the remaining therapeutic options for palliative or curative treatment postulate a difficult decision for the surgeon.
  • Palliative treatment protocols include systemic chemotherapy, ethanol instillation and chemoembolisation.
  • We report the case of a 21-year-old male patient who presented with a recurrent intrahepatic FLC, peritoneal karzinomatosis confined to the right lower abdomen including gastric, splenic, diaphragmatic and colon transversum metastasis 14 months after primary surgery.
  • We selected this patient as a reasonable candidate for an extended resection in trying to offer the optimal therapeutic modality.
  • Thus we performed a right hemihepatectomy, near complete resection of the right diaphragm, total gastrectomy with lymphadenectomy including en bloc resection of spleen, colon transversum, omentum majus and peritonectomy of the paravesical region.
  • Furthermore hyperthermic intraperitoneal chemotherapy was carried out the next day.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Cisplatin / administration & dosage. Hyperthermia, Induced. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Colectomy. Colonic Neoplasms / secondary. Colonic Neoplasms / surgery. Combined Modality Therapy. Follow-Up Studies. Gastrectomy. Hepatectomy. Humans. Infusions, Parenteral. Lymph Node Excision. Male. Omentum / surgery. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Peritoneum / surgery. Postoperative Care. Splenectomy. Splenic Neoplasms / secondary. Splenic Neoplasms / surgery. Stomach Neoplasms / secondary. Stomach Neoplasms / surgery. Time Factors

  • Genetic Alliance. consumer health - Fibrolamellar carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11370396.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Badreddine RJ, Prasad GA, Wang KK, Song LM, Buttar NS, Dunagan KT, Lutzke LS, Borkenhagen LS: Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus. Gastrointest Endosc; 2010 Apr;71(4):697-703
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus.
  • OBJECTIVE: To determine the rate and predictors of dysplasia/neoplasia recurrence after photodynamic therapy (PDT) in BE.
  • Recurrence was defined as the appearance of any grade of dysplasia or neoplasia after 2 consecutive endoscopies without dysplasia.
  • Entry histology, demographics, length of BE, presence and length of diaphragmatic hernia, EMR, stricture formation, nonsteroidal anti-inflammatory drug use, smoking, and the presence of nondysplastic BE or squamous epithelium were assessed for univariate associations.
  • Time-to-recurrence analysis was done by using Cox proportional hazards regression.
  • Median time to recurrence was 17 months (interquartile range 8-45 months).
  • CONCLUSION: Recurrence of dysplasia/neoplasia after PDT ablation is associated with advanced age, smoking, and residual BE.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):403-9 [17325482.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):56-64; quiz 351-2 [18996379.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1585-94 [17461453.001]
  • [Cites] Gastrointest Endosc. 2000 Jun;51(6):659-63 [10840296.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2000 Jul;10(3):409-19 [10899255.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1661-8 [10925965.001]
  • [Cites] Gastroenterology. 2000 Sep;119(3):624-30 [10982754.001]
  • [Cites] Gastrointest Endosc. 2001 May;53(6):554-8 [11323578.001]
  • [Cites] Dig Dis. 2000-2001;18(4):232-9 [11356995.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):225-9 [11774268.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1328-31 [12094845.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):461-7 [12145799.001]
  • [Cites] Mayo Clin Proc. 2002 Nov;77(11):1176-81 [12440553.001]
  • [Cites] Gastrointest Endosc. 2003 Aug;58(2):183-8 [12872083.001]
  • [Cites] Biomarkers. 2003 Nov-Dec;8(6):509-21 [15195681.001]
  • [Cites] Gut. 1990 Jan;31(1):4-10 [2318431.001]
  • [Cites] Am J Gastroenterol. 1996 Sep;91(9):1719-23 [8792687.001]
  • [Cites] Gastroenterology. 1998 Mar;114(3):448-55 [9496934.001]
  • [Cites] Gut. 1998 Dec;43(6):747-51 [9824599.001]
  • [Cites] Gastrointest Endosc. 1999 Jan;49(1):1-7 [9869715.001]
  • [Cites] Am J Med. 1999 Jun;106(6):642-9 [10378622.001]
  • [Cites] Gastrointest Endosc. 1999 Aug;50(2):165-72 [10425407.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Nov 15;20(10):1125-31 [15569115.001]
  • [Cites] J Pathol. 2005 Jan;205(1):57-64 [15586364.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Gastrointest Endosc. 2005 Apr;61(4):506-14 [15812401.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] World J Gastroenterol. 2005 Nov 14;11(42):6650-5 [16425359.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):60-6 [17185080.001]
  • [Cites] Gastrointest Endosc. 2007 Feb;65(2):185-95 [17258973.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1226-33 [17408660.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3):460-8 [17643436.001]
  • [Cites] Gut. 2007 Nov;56(11):1625-34 [17938435.001]
  • [Cites] Am J Gastroenterol. 2008 Jan;103(1):38-47 [18076737.001]
  • [Cites] Gut. 2008 Sep;57(9):1200-6 [18460553.001]
  • [CommentIn] Gastrointest Endosc. 2010 Apr;71(4):704-5 [20363412.001]
  • (PMID = 19959164.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK076845-04; United States / NCI NIH HHS / CA / R01 CA097048-05; United States / NCI NIH HHS / CA / R01CA097048; United States / NCI NIH HHS / CA / R01 CA111603; United States / NCI NIH HHS / CA / R03 CA135991; United States / NIDDK NIH HHS / DK / K08 DK076845-05; United States / NIDDK NIH HHS / DK / DK076845-04; United States / NCI NIH HHS / CA / R03CA135991-01; United States / NCI NIH HHS / CA / CA111603-05; United States / NIDDK NIH HHS / DK / K08 DK076845; United States / NCI NIH HHS / CA / CA097048-05; United States / NCI NIH HHS / CA / R01 CA111603-05; United States / NCI NIH HHS / CA / R01 CA097048; United States / NIDDK NIH HHS / DK / DK076845-05; United States / NCI NIH HHS / CA / R01 CA111603-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS248054; NLM/ PMC2981349
  •  go-up   go-down


8. Gouy S, Chereau E, Custodio AS, Uzan C, Pautier P, Haie-Meder C, Duvillard P, Morice P: Surgical procedures and morbidities of diaphragmatic surgery in patients undergoing initial or interval debulking surgery for advanced-stage ovarian cancer. J Am Coll Surg; 2010 Apr;210(4):509-14
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical procedures and morbidities of diaphragmatic surgery in patients undergoing initial or interval debulking surgery for advanced-stage ovarian cancer.
  • BACKGROUND: Surgical management of advanced-stage ovarian cancer (ASOC) can require diaphragmatic surgery (DS) to achieve complete cytoreduction.
  • The aim of this study was to evaluate modalities and morbidities of DS at the time of initial surgery (INS) and interval debulking surgery (IDS; performed after neoadjuvant chemotherapy).
  • STUDY DESIGN: Retrospective review of patients undergoing (unilateral or bilateral) DS at the time of INS or IDS for ASOC.
  • Treatment of the diaphragm was unilateral in 31 patients and bilateral in 32 patients.
  • DS was performed respectively at the time of INS in 22 patients (35%) and IDS in 41 (65%) patients.
  • Postoperative chest complications requiring treatment occurred in 6 cases: pulmonary embolism (3 cases), symptomatic pleural effusion requiring chest drainage (1 case), and pneumothorax necessitating chest drainage (2 cases).
  • Surgical treatment of this upper part of the abdomen is key to achieving complete cytoreductive surgery in ASOC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diaphragm / pathology. Diaphragm / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Ovariectomy. Peritoneal Neoplasms / surgery. Second-Look Surgery
  • [MeSH-minor] Abdominal Abscess / etiology. Adult. Aged. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Chemotherapy, Adjuvant. Chest Tubes / adverse effects. Clinical Competence. Digestive System Fistula / etiology. Female. Hematoma / etiology. Humans. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Staging. Patient Care Team. Pleural Effusion / etiology. Pneumothorax / etiology. Predictive Value of Tests. Prognosis. Pulmonary Embolism / etiology. Reoperation / adverse effects. Reoperation / methods. Retrospective Studies. Surgical Wound Dehiscence / etiology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American College of Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20347745.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


9. Nolè F, Munzone E, Mandalà M, Catania C, Orlando L, Zampino MG, Minchella I, Colleoni M, Peruzzotti G, Marrocco E, Goldhirsch A: Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study. Ann Oncol; 2001 Jan;12(1):95-100
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Chemotherapy regimens for patients with advanced breast cancer or large primary tumours (including locally advanced disease) usually contain anthracyclines, taxanes or both.
  • We assessed efficacy in terms of response rate and time to progression of a combination with continuous infusion 5-fluorouracil (5-FU), vinorelbine and cisplatin (ViFuP regimen), as a first or subsequent line treatment for metastatic breast cancer patients.
  • Therapy was given every three weeks.
  • Fifty-two patients had received prior chemotherapy for metastatic breast cancer, and sixty-one percent had previously received anthracyclines, thirty-five percent taxanes and twenty-nine percent 5-FU as a bolus injection.
  • After a median follow-up of 10.2 months, median duration of response is 5.2 months (range 1.5-20.7+ months), time to progression (TTP) is 6.8 months (range 0.3-24.7 months).
  • Eleven patients developed a right diaphragmatic supra elevation, while deep vein thrombosis, central venous catheter associated, occurred in eight patients.
  • CONCLUSIONS: We identified a combination chemotherapy with noteworthy efficacy and well tolerated subjectively as either a first- or second-line treatment for metastatic breast cancer patients.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11249057.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Eroğlu A, Kürkçüoğlu IC, Karaoğlanoğlu N, Alper F, Gündoğdu C: Extraskeletal Ewing sarcoma of the diaphragm presenting with hemothorax. Ann Thorac Surg; 2004 Aug;78(2):715-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal Ewing sarcoma of the diaphragm presenting with hemothorax.
  • Ewing sarcoma is a relatively uncommon malignant bone neoplasm that usually occurs in children and young adults and involves the major long bones, pelvis, and ribs.
  • Primary diaphragmatic Ewing sarcoma is extremely rare.
  • To the best of our knowledge, only three cases of primary Ewing sarcoma of the diaphragm have been reported.
  • After drainage, a roentgenogram film, computed tomography, ultrasonography, and magnetic resonance image showed a giant mass on the right diaphragm.
  • Primary diaphragmatic tumor was resected totally by right posterolateral thoracotomy, and histologically, an extraskeletal Ewing sarcoma was identified.
  • The patient received adjuvant radio-chemotherapy, and there was no evidence of disease 10 months after the operation.
  • Although extremely rare, extraskeletal Ewing sarcoma should be kept in mind in the differential diagnosis of diaphragmatic soft tissue tumors.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Dyspnea / etiology. Female. Hemothorax / etiology. Humans. Ifosfamide / administration & dosage. Mesna / administration & dosage. Neoplasm Invasiveness. Organ Specificity. Radiotherapy, Adjuvant. Remission Induction. Ribs / pathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15276562.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; MAID protocol
  •  go-up   go-down


11. Patterson H, Norman AR, Mitra SS, Nicholls J, Fisher C, Dearnaley DP, Horwich A, Mason MD, Huddart RA: Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol; 2001 Apr;59(1):5-11
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone.
  • PURPOSE: To assess the results of treatment in 33 patients with stage IIA/B seminoma who were treated with carboplatin and radiotherapy (RT) between January 1989 and December 1996.
  • PATIENTS AND METHODS: Thirty patients received single course single agent carboplatin (400 mg/m2 or area under curve (AUC 7), two patients received two courses carboplatin, and one patient received single course carboplatin and etoposide, all 4-6 weeks prior to infra-diaphragmatic RT.
  • With a median follow-up of 4 years (range 2-70 months) 2/33 patients treated with chemotherapy and RT have relapsed, 5-year relapse free survival (RFS) = 96.9% (95% confidence interval (CI) 72.9-99.4%), and one patient has died of progressive disease, 5-year overall survival (OS) = 96.7%.
  • With a median follow-up of 11.2 years (range 6 months to 25.8 years) 15/80 patients treated with RT alone have relapsed, 5-year RFS = 80.7% (95% CI 70.1-87.9%), including 13/61 patients treated with infra-diaphragmatic RT, 5-year RFS = 77.9%, and 2/19 treated with additional supra-diaphragmatic RT, 5-year RFS = 89.5% (P = 0.277).
  • For stage IIA, 1/14 patients treated with chemotherapy and RT have relapsed, 5-year RFS = 92.3%, compared with 5/34 treated with infra-diaphragmatic RT alone 5-year, RFS = 84.9% (P = 0.527).
  • For stage IIB, 1/19 patients relapsed (at 69 months) following chemotherapy and RT (5-year RFS = 100%), whereas 8/27 relapsed following infra-diaphragmatic RT alone, 5-year RFS = 69.4% (P = 0.0595).
  • [MeSH-major] Carboplatin / administration & dosage. Radiotherapy / methods. Seminoma / drug therapy. Seminoma / radiotherapy. Testicular Neoplasms / drug therapy. Testicular Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiation Dosage. Reference Values. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Radiother Oncol. 2001 Apr;59(1):1-3 [11295199.001]
  • (PMID = 11295200.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin
  •  go-up   go-down


12. Bonnette P: [Radical surgery for mesothelioma]. Cancer Radiother; 2007 Jan-Feb;11(1-2):101-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The high rate of peritoneal (26-31%), controlateral pleural and pericardial recurrences justify the routine practice of preoperative laparoscopy and controlateral thoracoscopy and a pleuropneumonectomy without pericardotomy and diaphragmatic resection.
  • The diaphragm is lowered to facilitate radiotherapy.
  • Chemotherapy may be performed postoperatively.
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Laparoscopy. Neoplasm Recurrence, Local / pathology. Pleura / surgery. Pneumonectomy. Radiotherapy, Adjuvant. Thoracoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949849.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 18
  •  go-up   go-down


13. Deffieux X, Castaigne D, Pomel C: Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:35-40
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We focused on three sites of carcinomatosis: bowel, liver pedicle, and right diaphragmatic dome.
  • These women underwent neoadjuvant chemotherapy in the following 2 weeks.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Digestive System Surgical Procedures. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Neoplasm Staging. Patient Selection

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515565.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Greer BE, Swensen RE, Gray HJ: Surgery for ovarian cancer: rationale and guidelines. J Natl Compr Canc Netw; 2004 Nov;2(6):561-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Goals of primary surgery for ovarian cancer are to establish diagnosis, proper staging, determination of prognosis, and optimal cytoreduction of gross disease before chemotherapy for improved outcome.
  • In addition to standard removal of the ovaries, uterus, omentum, and pelvic and para-aortic lymph nodes for early disease, extended surgical techniques used to debulk advanced disease include bowel resection, splenectomy, partial liver resection, peritoneal or diaphragmatic stripping, and use of laser or ultrasound (CUSA).
  • Second-look procedures were performed historically to determine response to chemotherapy to delineate duration of treatment, but now are best used in a research setting with the advent of improved chemotherapeutic agents.
  • As a high percentage of patients have a gynecologic malignancy recurrence after primary treatment, many practitioners perform secondary cytoreductive procedures for recurrent disease.
  • [MeSH-minor] Disease Progression. Female. Humans. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Laparotomy / methods. Neoplasm Staging / methods. Ovariectomy / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19780300.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


15. Thuilliez C, Watrelot-Virieux D, Chanut F, Fournel-Fleury C, Ponce F, Marchal T: Presumed primary muscular lymphoma in a dog. J Vet Diagn Invest; 2008 Nov;20(6):824-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite chemotherapy, health status declined and the animal was euthanized a few weeks later.
  • Other muscles were infiltrated by the same neoplasm (diaphragm and intercostal, abdominal, and gluteal muscles) indicating a probable multicentric origin.
  • Histological examination confirmed the diagnosis of anaplastic large cell lymphoma, which showed a strong muscular tropism.
  • The presumed histological diagnosis in this dog was primary muscular anaplastic large T-cell lymphoma.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18987239.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Trousse DS, Avaro JP, D'Journo XB, Doddoli C, Astoul P, Giudicelli R, Fuentes PA, Thomas PA: Is malignant pleural mesothelioma a surgical disease? A review of 83 consecutive extra-pleural pneumonectomies. Eur J Cardiothorac Surg; 2009 Oct;36(4):759-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preoperative chemotherapy consisting of a doublet cisplatin-pemetrexed (mean of three cycles) was offered to 10 patients (12%).
  • Postoperative therapies, either chemotherapy or radiotherapy, were given in 25 patients (30%).
  • Re-operation was necessary in 12 cases (14.5%) for one of the following reasons: broncho-pleural fistula (n=4), bleeding (n=3), diaphragmatic patch rupture (n=3), oesophago-pleural fistula (n=1) and empyaema (n=1).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pleura / surgery. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19523843.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


17. Corapçioglu F, Sarper N, Demir H, Güvenç BH, Sözübir S, Akansel G, Berk FS: A child with undifferentiated sarcoma of the liver complicated with bronchobiliary fistula and detected by hepatobiliary scintigraphy. Pediatr Hematol Oncol; 2004 Jul-Aug;21(5):427-33
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 12-year-old boy was diagnosed to have USL of the right liver lobe, invading the diaphragm.
  • An extended right hepatectomy and total resection of the mass was performed, leaving patchy tumoral invasion of the anterior diaphragmatic surface followed by combined chemotherapy regimen.
  • Hepatobiliary scintigraphy is the useful diagnostic procedure to define bronchobiliary fistula in children with liver tumor and clinical suspicion of bronchobiliary fistula.
  • [MeSH-minor] Child. Humans. Male. Neoplasm, Residual. Reoperation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15205086.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] QTJ2VIW97T / Technetium Tc 99m Disofenin
  •  go-up   go-down


18. Wu M, Shen K, Lang JH, Huang RL, Huang HF, Pan LY: [Clinical analysis of prognostic factors for stage III ovarian epithelial carcinoma]. Zhonghua Yi Xue Za Zhi; 2005 Jun 1;85(20):1406-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the prognostic factors for stage III ovarian epithelial carcinoma so as to provide scientific basis for further reasonable therapy.
  • During the operation, 150 cases (41.8%) and 265 cases (71.8%) were found with intestinal and diaphragmatic involvement respectively.
  • Pathologic results showed that serous type was the most common histological type (48.9%) and mucinous type was the least one (2.2%).
  • 290 cases with effective response to surgery underwent chemotherapy for 3-22 (10 +/- 4) courses.
  • Multivariate analysis revealed that intestinal involvement, diaphragmatic invasion, tumor residuals, and course number of chemotherapy were significantly correlated with prognosis (P < 0.01, < 0.05, < 0.01, and < 0.01 respectively).
  • CONCLUSION: Cytoreduction for the tumor in peritoneal cavity and positive chemotherapy should be emphasized sufficiently and may be helpful for the prognosis of stage III ovarian epithelial carcinoma.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029654.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Fullerton DA, López F, Avendaño R, Aparicio R, Wistuba I: [Atypical presentation of a colorectal carcinoma]. Rev Med Chil; 2004 Aug;132(8):985-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Cáncer colorrectal de presentación atípica.
  • A thorax CAT scan showed a proliferating mass in the splenic angle of the colon, with left lung and diaphragmatic invasion.
  • Endoscopic biopsies confirmed the diagnosis of adenocarcinoma.
  • The patient underwent a subtotal colectomy with partial excision of diaphragm and left lung.
  • The pathological report showed a mucosecretory adenocarcinoma, infiltrating the pericolonic adipose tissue without adjacent organ infiltration and a chronic inflammatory process involving colonic serosa, diaphragm pleura, and lung.
  • Adjuvant chemotherapy was indicated and the patient is asymptomatic and without evidences of tumor recurrence after a 24 months follow up.
  • [MeSH-major] Adenocarcinoma, Mucinous. Colorectal Neoplasms. Diaphragm. Lung Neoplasms. Muscle Neoplasms / pathology
  • [MeSH-minor] Aged. Follow-Up Studies. Humans. Male. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15478301.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


20. Catani M, De Milito R, Simi M: [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location]. Chir Ital; 2005 Jan-Feb;57(1):127-33
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location].
  • [Transliterated title] Nuovi orientamenti nella cura dei tumori stromali gastroenterici (GIST) avanzati e metastatici: trattamento combinato intervento chirurgico-terapia sistemica con imatinib in un caso a localizzazione primitiva gastrica.
  • Gastrointestinal stromal tumours (GIST) are rare neoplasms originating from connective tissue in the digestive tract with an incidence of less than 1% and account for most non-epithelial primitive digestive tumours.
  • Metastasis diagnosed at the time of disease discovery confirms GIST malignancy.
  • Resistance to conventional chemotherapy is commonly shown by malignant GIST.
  • At the time of the first operation the patient had lost 10 kg body weight over the previous months and was seriously cachectic.
  • Considering the action mechanism of imatinib and the extent of the lesion we decided to perform a total gastrectomy procedure.
  • At the time of the operation the stomach seemed to have a modified volume and shape: it appeared to be divided into two sacs, the larger and deeper of which was the original gastric cavity, while the superficial, smaller one seemed to be a protrusion of the organ.
  • The stomach was indistinguishable from the spleen, the transverse colon and the distal pancreatic tract.
  • The neoplasm was directly linked to the left liver and to the inferior diaphragmatic surface.
  • The patient was discharged on postoperative day 8 and commenced imatinib therapy 30 days after the operation with 4 tablets per day.
  • One year after the operation the outcome appears to be lasting and the patient has tolerated the drug treatment well.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrectomy. Gastrointestinal Stromal Tumors / therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Stomach Neoplasms / therapy
  • [MeSH-minor] Adult. Benzamides. Humans. Imatinib Mesylate. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15832750.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


21. Yamamuro M, Gerbaudo VH, Gill RR, Jacobson FL, Sugarbaker DJ, Hatabu H: Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol; 2007 Dec;64(3):356-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because of its excellent contrast resolution, MRI is superior to CT, both in the differentiation of malignant from benign pleural disease, and in the assessment of chest wall and diaphragmatic involvement.
  • In MPM, therapeutic effects of chemotherapy can be monitored with perfusion MRI.
  • It has been shown that FDG-PET is useful for the differentiation of benign from malignant lesions, for staging and monitoring metabolic response to therapy against MPM, and that it has prognostic value.
  • [MeSH-major] Diagnostic Imaging / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Humans. Magnetic Resonance Imaging / methods. Neoplasm Staging. Neovascularization, Pathologic / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954021.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Number-of-references] 61
  •  go-up   go-down


22. Schouwink H, Rutgers ET, van der Sijp J, Oppelaar H, van Zandwijk N, van Veen R, Burgers S, Stewart FA, Zoetmulder F, Baas P: Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results. Chest; 2001 Oct;120(4):1167-74
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results.
  • OBJECTIVE: To determine the optimal administered dose of meta-tetrahydroxyphenylchlorin (mTHPC) for intraoperative photodynamic therapy (IPDT) in resected malignant pleural mesothelioma (MPM).
  • The primary objective of this combination treatment was to improve local tumor control.
  • The real-time fluence rate measurements were performed using four isotropic detectors in the chest cavity to calculate the total light dose.
  • Three patients died in the perioperative period, and one death was directly related to photodynamic therapy.
  • Real-time dosimetry identified 12 patients in whom additional illumination had to be given to the diaphragmatic sinuses, which were unavoidably shielded during integral illumination.
  • The median survival time for all 28 patients was 10 months.
  • Local tumor control, 9 months after treatment, was achieved in 13 of the 26 patients treated with IPDT.
  • The considerable toxicity associated with the procedure, however, precludes its recommendation for widespread use.
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Mesoporphyrins / administration & dosage. Mesoporphyrins / adverse effects. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Chest. 2002 Nov;122(5):1866-7; author reply 1867 [12426299.001]
  • (PMID = 11591556.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mesoporphyrins; FU21S769PF / temoporfin
  •  go-up   go-down


23. Menczer J, Chetrit A, Sadetzki S, National Israel Ovarian Cancer Group: Ovarian carcinoma apparently confined to the ovaries--the accuracy of surgical staging in Israel. Eur J Gynaecol Oncol; 2009;30(4):375-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In order to allot an ovarian malignancy to FIGO Stage I, in addition to abdominal exploration and the basic operation, it is also necessary to do peritoneal washings for cytological examination, random peritoneal biopsies (including diaphragmatic assessment) and omental and retroperitoneal lymph node assessment.
  • The most commonly performed staging procedure was omental assessment (85.2%) while peritoneal biopsy was the least common one (34.1%).
  • CONCLUSION: Although the data are from a decade ago, they seem to indicate the need for an increased awareness of the necessity for accurate surgical staging of tumors apparently confined to the ovaries since it can identify a group of patients who require surgical therapy alone and who can be spared the complications, inconvenience and cost of adjuvant chemotherapy.
  • [MeSH-major] Carcinoma / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Female. Humans. Middle Aged. Neoplasm Staging. Omentum / pathology. Ovary / pathology. Peritoneum / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19761125.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Investigator] Anderman S; Alteras M; Anteby S; Atad J; Avni A; Bar-Am A; Beck D; Beller U; Ben-Baruch G; Ben-David Y; Ben-Shlomo I; Biran H; Ben Ami M; Chetrit A; Cohen S; Cohen S; Dgani R; Fishler Y; Fishman A; Friedman E; Gemer O; Gershoni R; Halperin R; Hirsh-Yechezkel G; Idelman D; Katan R; Kopilovic Y; Lahad E; Geva LL; Levavi H; Levy T; Levit A; Lifschitz-Mercer B; Lubin F; Leviatan Z; Marcovich J; Menczer J; Modan B; Nitzan H; Oetinger M; Perez T; Piura B; Schneider D; Shteiner M; Tal Z; Yaffe C; Yanai I; Zohar S
  •  go-up   go-down






Advertisement